Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 21Neoplasms 6Neoplasm Metastasis 5Ovarian Neoplasms 3Endometrial Neoplasms 3Triple Negative Breast Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Hereditary Sensory and Autonomic Neuropathies 2Fallopian Tube Neoplasms 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Breast Diseases 2von Hippel-Lindau Disease 1Uterine Cervical Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Solid Tumors Refractory to Standard Therapy 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma 1Recurrence 1Rare Tumor 1Pancreatic Neoplasms 1Neoplasms by Site 1Neoplasm, Residual 1Melanoma 1Medulloblastoma 1Malignant Female Reproductive System Neoplasm 1Lung Neoplasms 1

Interventions

ribociclib 1palbociclib 1giredestrant 1abemaciclib 1Gonadotropin-Releasing Hormone 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer × palbociclib × Clear all
NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Recruiting
1,050 enrolled
Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡